The company's net earnings rose, and it reaffirmed its guidance of $195 million to $200 million in revenues for full year 2016.
The LAMP-based test is faster and more sensitive, allowing faster treatment and more accurate diagnosis for malaria patients.
There were more winners than losers in the 2015 GWDN Index, but some lost big.
The company's direct-from-blood test detects low levels of plasmodium parasitemia and runs on Meridian's Illumigene isothermal molecular diagnostic platform.
Oasis, based in Vancouver, Washington, develops, manufactures, and sells pre-analytic tools for collecting, preserving, and transporting saliva and other oral fluids.
The Cincinnati, Ohio-based molecular diagnostics manufacturer reaffirmed fiscal 2016 guidance and declared a cash dividend.
A number of firms now have FDA-approved Group A Strep assays, but end users may be hesitant to adopt them until Infectious Disease Society of America guidelines are updated.
The company also said that it expects to report fiscal 2015 revenues and EPS at the low end of its previously stated guidance range.
Meridian's Diagnostics segment grew 2 percent lifted by a 10 percent increase in revenues from the illumigene molecular product line.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.